The use of anti-EGFR monoclonal antibodies-EGFR blockers in the comprehensive treatment of metastatic colorectal cancer with or without the surgical removal of metastases
- Authors: Kit O.I1, Vladimirova L.Y.1, Abramova N.A.1, Storozhakova A.E1, Kalabanova E.A1, Kabanov S.N1, Popova I.L1, Novoselova K.A1, Tkhanovskaya N.M1, Agieva A.A1, Snezhko T.A1, Samaneva N.Y1
-
Affiliations:
- Russian Scientific Research Institute of Oncology
- Issue: Vol 21, No 1-2 (2016)
- Pages: 66-71
- Section: Articles
- URL: https://journals.rcsi.science/1028-9984/article/view/40333
- DOI: https://doi.org/10.18821/1028-9984-2016-21-1-66-71
- ID: 40333
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
O. I Kit
Russian Scientific Research Institute of OncologyRostov-on-Don, 344037, Russian Federation
L. Yu Vladimirova
Russian Scientific Research Institute of OncologyRostov-on-Don, 344037, Russian Federation
Nataliya A. Abramova
Russian Scientific Research Institute of Oncology
Email: pylulkin@mail.ru
MD, PhD, Senior Researcher of the Department of Drug Treatment of Tumors Rostov-on-Don, 344037, Russian Federation
A. E Storozhakova
Russian Scientific Research Institute of OncologyRostov-on-Don, 344037, Russian Federation
E. A Kalabanova
Russian Scientific Research Institute of OncologyRostov-on-Don, 344037, Russian Federation
S. N Kabanov
Russian Scientific Research Institute of OncologyRostov-on-Don, 344037, Russian Federation
I. L Popova
Russian Scientific Research Institute of OncologyRostov-on-Don, 344037, Russian Federation
K. A Novoselova
Russian Scientific Research Institute of OncologyRostov-on-Don, 344037, Russian Federation
N. M Tkhanovskaya
Russian Scientific Research Institute of OncologyRostov-on-Don, 344037, Russian Federation
A. A Agieva
Russian Scientific Research Institute of OncologyRostov-on-Don, 344037, Russian Federation
T. A Snezhko
Russian Scientific Research Institute of OncologyRostov-on-Don, 344037, Russian Federation
N. Y Samaneva
Russian Scientific Research Institute of OncologyRostov-on-Don, 344037, Russian Federation
References
- Jemal A. Global cancer statistics. C.A. Cancer J. Clin. 2011; 2 (61): 69-90.
- Беляева А.В. Мутации в гене K-ras у больных колоректальным раком: эпидемиология и клиническое значение: Дисс. ...канд. мед. наук. СПб.; 2012.
- Архипова О.Е., Черногубова Е.А., Лихтанская Н.В., Тарасов В.А., Кит О.И., Матишов Д.Г. Анализ встречаемости онкологических заболеваний в ростовской области. Пространственно-временная статистика Фундаментальные исследования. 2013; 7-3: 504-10.
- Кит О.И. Проблема колоректального рака в начале ХХI века: достижения и перспективы. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2013; 23 (3): 65-71.
- Allegra C.J., Jessup J.M., Somerfield M.R. et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J. Clin. Oncol. 2009; 27 (12): 2091-6.
- Amado R., Wolf M., Peeters M. et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 2008; 26: 1626-34.
- Van Cutsem E., Peeters M., Siena S. et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J. Clin. Oncol. 2007; 25: 1658-64.
- Владимирова Л.Ю., Геворкян Ю.А., Абрамова Н.А. и др. Оценка эффективности и токсичности моноклонального антитела к EGFR панитумумаба при колоректальном раке. В кн.: VII Съезд онкологов и радиологов стран СНГ. 2012.
- Van Cutsem E., Humblet Y. et al. Cetuximab dose-escalation study in patients with nCRC with no or slight skin reaction on cetuximab standard dose treatment (EVEREST): preliminary PK and efficacy date of a randomized study. In: Proceedings of ASCO 2007. 2008: Abstr. 237.
- Peeters M., Price T., Hotko Y. et al. Randomized phase 3 study of panitumumab with FOLFIRI vs FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC). Eur. J. Cancer. 2009; 7 (3, Suppl.): 14LBA.
- Price T. et al. ASPECCT: a randomized, multicenter, open-label, phase 3 study of panitumumab (pmab) vs cetuximab (cmab) for previously treated wild-type (WT) KRAS metastatic colorectal cancer (mCRC). In: The European Cancer Congress 2013. Sep 29. 2014: Abstr. 18.
- Stintzing S., Jung A., Rossius L. et al: Analysis of KRAS/NRAS and BRAF mutations in FIRE-3: A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients. In: The European Cancer Congress 2013, Sep. 29. 2013: Abstr. 17.
- Cascinu S., Rosati G., Nasti G., Lonardi S. et al. A phase III multicenter trial comparing two different sequences of second/third line therapy (irinotecan/cetuximab followed by FOLFOX-4 vs. FOLFOX-4 followed by irinotecan/cetuximab in K-RAS wt metastatic colorectal cancer (mCC) patients refractory to FOLFIRI/Bevacizumab. Eur. J. Cancer. 2015; 51 (Suppl. S3): S329.
- Abramova N., Vladimirova L.Yu., Kit O.I. Monoclonal antibodies against EGFR-receptors in metastatic colorectal cancer (mCRC) treatment: comparative tolerability and efficacy of Panitumumab (P) and Cetuximab (C). In: ASCO Annual Meeting. 2014. Abstr. 1070.
- Douillard J., Siena S., Cassidy J. et al. Randomized phase 3 study of panitumumab with FOLFOX4 vs FOLFOX4 alone as firstline treatment in patients with metastatic colorectal cancer: the PRIME trial. Eur. J. Cancer. 2009; 7 (3, Suppl.): 10LBA.
- Humblet Y., Peeters M., Siena S. et al. Association of skin toxicity (ST) severity with clinical outcomes and health-related quality of life (HRQoL) with panitunumab (Pmab). In: American Society of Clinical Oncology. Chicago; 2007: Abstr. 4038.
- Vladimirova L.Y., Kit O.I., Nikipelova E.A. et al. Resilts of monoclonal antibodies against EGFR-receptors application in patients with metastatic colorectal cancer. J. Clin. Oncol. 2013; 31 (Suppl. 15: 49 Annual Meeting of ASCO): 800S. e19047.
- Варламова С.Е., Антимоник Н.Ю., Козлова Н.М., Макеев Ю.М., Бердов Б.А., Болотина Л.В. и др. Отечественный опыт профилактики и лечения проявлений кожной токсичности у пациентов мКРР, получающих ингибиторы EGFR, на примере панитумумаба. Проект RUSSCO по разработке рекомендаций по коррекции дерматологических реакций у пациентов, получающих терапию ингибиторами EGFR. Злокачественные опухоли. 2013; 3: 42-51.
- Folprecht G., Gruenberger T., Bechstein W.O. et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 2010; 11 (1): 38-47.
- Kopetz S., Chang G.J., Overman M.J. et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J. Clin. Oncol. 2009; 27 (22): 3677-83.
- Nordlinger B., van Cutsem E., Gruenberger T. et al. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann. Oncol. 2009; 20 (6): 985-92.